Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna™ to Present at the Stifel 2019 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 13, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive...
View HTML
Toggle Summary Dicerna™ Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress
— Initiated Dosing of Patients With Primary Hyperoxaluria Types 1 and 2 in PHYOX™2 Pivotal Clinical Trial — — Announced Collaboration Agreement With Roche for Development of DCR-HBVS Including Option to Co-Fund Pivotal Development and Co-Promote in the U.S....
View HTML
Toggle Summary Dicerna™ to Report Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 4, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2019 financial...
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 1, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved...
View HTML
Toggle Summary Dicerna™ Enters Agreement with Roche to Develop and Commercialize DCR-HBVS for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
– Roche to gain worldwide license to Dicerna’s novel RNAi therapy currently in Phase 1 – – Dicerna to receive $200 million up front plus up to $1.47 billion in potential milestone payments related to DCR-HBVS – – Dicerna to retain option to co-fund pivotal development of DCR-HBVS worldwide and...
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 1, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved...
View HTML
Toggle Summary Dicerna™ to Present at Two Upcoming Investor Conferences
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 25, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that management will present at two investor conferences in...
View HTML
Toggle Summary Dicerna™ Appoints Patrick Gray to Board of Directors to Support Continued Growth
Company Announces Retirement of Board of Director Veteran Dennis Langer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 19, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of...
View HTML
Toggle Summary Dicerna™ Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved...
View HTML
Toggle Summary Dicerna™ to Present at H.C. Wainwright 21st Annual Global Investment Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive...
View HTML